Resources
- Cancer Center and Research Institute
-
Cancer Research
- Cancer Research Overview
-
Cancer Registries
- Cancer Registries Home
- UMMC Cancer Registry
- Mississippi Cancer Registry
- Clinical Trials
- Programs
- For Students and Trainees
- Patient Support
- Give Now
- In the News
- Contact Cancer Center and Research Institute
- CCRI Leadership
Newsletter Fall 2020
Mississippi Cancer Registry
September 2020 | Volume 15 Issue 3
Educational Corner
Abstracting Resources
Upcoming Webinars | CTR Exam Dates
Congratulations!
Announcement
MCR Staff
Educational Corner
CHANGES, CHANGES, CHANGES……
Upcoming changes for 2021 (for cases diagnosed 01/01/2021 or after):
*Post-therapy Clinical yc Staging:
- What is yc staging?
- Staging after neoadjuvant treatment, but before surgery of the primary site
- Why is yc stage necessary?
- Shows patient treatment plan initially included surgery
- Treatment plan changed due to "good" or "poor" response
- Shows exact level of response compared to clinical stage
Registrar never assigns more than 2 AJCC stage classifications
- Only ask for yc when yp cannot be assigned
- Provides assessment of response, which is the difference between cTNM and ycTNM
- When yc staging must be used
- yc assigned when
- Treatment plan is neoadjuvant followed by surgery
- But surgery is canceled
- yc assigned when
- yc includes:
- Evaluation by physical exam, imaging, biopsy, and any diagnostic procedures
- When yc staging must be used
- Examples of yc staging:
- Patient doesn’t respond to neoadjuvant treatment, surgery is canceled
- Patient responds so well, surgery is no longer indicated
(Resource: Update on AJCC 8th Edition TNM Staging Webinar by Donna Gress, RHIT, CTR)
Additional Changes for 2021:
*AJCC to Release Version 9 Cervix Uteri Cancer Staging System:
The new Version 9 content, presented in a streamlined, easy-to-use format, incorporates the 2018 Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) staging classification, as well as the World Health Organization (WHO) 2020 Classification of Tumors histology codes. Physicians, registrars, researchers, and other content users will be able to purchase the electronic format of the updated Cervix Uteri content, including tables, explanatory notes and illustrations, starting October 25, 2020. Version 9 becomes effective on January 1, 2021, and replaces the 8th Edition Cervix Uteri cancer site content. All other disease sites in the 8th Edition Cancer Staging Manual remain current for 2021.
*CDC-NPCR Requirement:
Beginning 01/01/2021, all GIST tumors are reportable and will use the behavior code /3.
*ICD-O:
ICD-O Site/Type Validation Update for cases diagnosed 01/01/2021 and after can be found at the following link https://seer.cancer.gov/icd-o-3/errata.sitetype.20200629.pdf
*Solid Tumor Rules:
Melanoma is the only new Solid Tumor Rule chapter that will be released in 2021, release date unknown at this time. Based on the recent WHO 4th Ed Tumors of Skin, we do not expect major changes to the cutaneous melanoma rules.
FLccSC
Fundamental Learning Collaborative for the Cancer Surveillance Community:
The FlccSC site is up and running. If you have not yet registered, you can do so at the link below. The MS FLccSC site will stay updated with current news, webinars and educational opportunities. You do not want to miss out!
For more information, contact: Angel Davis, CTR, RHIT – adavis6@umc.edu
Abstracting Resources
AJCC Cancer Staging Manual
Cases with a diagnosis date of 01/01/2018 and forward should be staged using the AJCC 8th Edition Cancer Staging Manual. The 3rd printing 2018 Edition is now available.
Please visit https://cancerstaging.org/references-tools/deskreferences/Pages/8EUpdates.aspx# for all 8th Edition updates and corrections. For all other information, visit https://cancerstaging.org/Pages/default.aspx.
Summary Stage 2018
The 2018 version of Summary Stage applies to every site and/or histology combination, including lymphomas and leukemias. Summary Stage uses all information available in the medical record; in other words, it is a combination of the most precise clinical and pathological documentation of the extent of disease. The Summary Stage 2018 manual is available at https://seer.cancer.gov/tools/ssm/.
Site Specific Data Items (SSDI)
Site Specific Data Items (SSDI) are similar to the Site Specific Factors (SSF) collected with Collaborative Stage. These data items are specific to certain site/histology combinations. For example, the SSDIs for breast will be used to collect information such as estrogen receptor status, progesterone receptor status, Her2 status, Nottingham grade, and additional information related to primary tumors of the breast. The information collected in these data items are specific to breast. The SSDI manual is available at https://apps.naaccr.org/ssdi/list/.
Grade
Beginning with cases diagnosed in 2018, grade information will be collected in three fields: Clinical Grade, Pathological Grade, and Post-Therapy Grade. Within the Grade Manual, you will find definitions for the three new grade data items, coding instructions, and the site/histology specific grade tables. The Grade manual is available at https://www.naaccr.org/SSDI/Grade-Manual.pdf?v=1527859766.
SEER Hematopoietic and Lymphoid Neoplasm Database
This provides data collection rules for hematopoietic and lymphoid neoplasms for 2010+. The SEER Hematopoietic and Lymphoid Neoplasm manual is available at https://seer.cancer.gov/tools/heme/Hematopoietic_Instructions_and_Rules.pdf.
2018 Solid Tumor Coding Manual
Use the 2018 Solid Tumor coding rules to determine the number of primaries to abstract and the histology to code for cases diagnosed 2018 and forward. The Solid Tumor coding rules replace the 2007 Multiple Primary and Histology (MP/H) Rules. The manual is available at https://seer.cancer.gov/tools/solidtumor/. The change log contains updates made to the FINAL module sections. This does not include changes made to the drafts.
CoC 2018 STORE Manual
The STORE Manual has replaced the FORDS Manual. The STORE is now available at https://www.facs.org/quality-programs/cancer/ncdb/registrymanuals/cocmanuals.
Upcoming Webinars
NAACCR
10/1/20 Prostate
- Guest Host: Wilson Apollo
11/5/20 Lung
- Guest Host: Denise Harrison, Kelli Olsen
For more information, contact: Angel Davis, adavis6@umc.edu
Upcoming CTR Exam
2021 EXAM TESTING WINDOWS
The October 16 - November 6, 2020 testing window is expanded to start on October 12 and run through November 14, 2020.
Application Deadline: October 11
For more information, visit: www.ncra-usa.org/CTRMCR Staff
Director UMMC & MCR: Deirdre Rogers, dbrogers@umc.edu
MCR Manager: La'Tawnya Roby, ldroby@umc.edu
Clinical Systems Analyst-Intermediate: Tresheena Boyd, tboyd@umc.edu
Data Quality Analyst-Trainer: Angel Davis, adavis6@umc.edu
Data Quality Analyst-Auditor: April Huggins, ahuggins@umc.edu
Electronic Data Source Coordinator: Lisa Hamel, lhamel@umc.edu
Cancer Registrars:
- Stacy Major, semajor@umc.edu
- Stephanie N. Engelman, nengelman@umc.edu
- LaToya Bogan, lbogan@umc.edu
- Cameron Proctor, cproctor@umc.edu
Administrative Assistant: Ophelia Spencer, ospencer@umc.edu